Compare MRT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRT | IPHA |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | Turkey | France |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 165.3M |
| IPO Year | 2021 | 2014 |
| Metric | MRT | IPHA |
|---|---|---|
| Price | $2.07 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.58 | ★ $5.75 |
| AVG Volume (30 Days) | 51.8K | ★ 52.7K |
| Earning Date | 08-08-2018 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $72.36 | $180.36 |
| Revenue Next Year | $95.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $1.18 |
| 52 Week High | $2.75 | $2.71 |
| Indicator | MRT | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 41.28 |
| Support Level | $1.99 | $1.67 |
| Resistance Level | $2.24 | $1.95 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 34.15 | 0.00 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.